# EDGAR Filing Document

**Accession Number:** 0001446159
**File Stem:** 0001171843-25-003768
**Filing Date:** 2025-6
**Character Count:** 19342
**Document Hash:** 2d47ad086cf576ea05b49bb44603bd8b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-25-003768.hdr.sgml**: 20250606

**ACCESSION NUMBER**: 0001171843-25-003768

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250602

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250606

**DATE AS OF CHANGE**: 20250606

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Predictive Oncology Inc.
- **CENTRAL INDEX KEY:** 0001446159
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 331007393
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36790
- **FILM NUMBER:** 251031197

**BUSINESS ADDRESS:**
- **STREET 1:** 91 43RD STREET
- **STREET 2:** SUITE 110
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15201
- **BUSINESS PHONE:** 412-432-1500

**MAIL ADDRESS:**
- **STREET 1:** 91 43RD STREET
- **STREET 2:** SUITE 110
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15201

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Precision Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20180314

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Precision Therapeutic Inc.
- **DATE OF NAME CHANGE:** 20180208

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Skyline Medical Inc.
- **DATE OF NAME CHANGE:** 20130807

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 2, 2025**

**Predictive Oncology Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36790** | **33-1007393** |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

**91 43<sup>rd</sup> Street, Suite 110**

**Pittsburgh, Pennsylvania 15201**

**(412) 432-1500**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

---

| | |
|:---|:---|
| **Josh Blacher** | ***Copy to:*** |
| **Interim Chief Financial Officer** | **Alan Seem** |
| **Predictive Oncology Inc.** | **DLA Piper LLP (US)** |
| **91 43<sup>rd</sup> Street, Suite 110** | **3203 Hanover Street, Suite 100** |
| **Pittsburgh, Pennsylvania 15201** | **Palo Alto, California 94304** |
| **(412) 432-1500** | **(650) 833-2000** |
| (Name, address and telephone number of agent for service) |  |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common stock, par value $0.01 per share | POAI | NASDAQ Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 8.01.** | **Other Events.** |

---

On June 2, 2025, Predictive Oncology Inc., a Delaware corporation, (the "Company"), filed a prospectus supplement, which amended and supplemented certain information in the prospectus supplement, dated April 18, 2025, to the prospectus, dated May 21, 2024, filed with the Securities and Exchange Commission as part of its registration statement on Form S-3 (333-279123), as supplemented by its prospectus supplement, dated May 21, 2024 (collectively, the "ATM Prospectus"). The Company previously entered into an ATM Sales Agreement (the "Agreement") on May 3, 2024 with H.C. Wainwright & Co., LLC ("Wainwright"), as sales agent to sell shares of the Company's common stock, par value $0.01 per share, from time to time, through an "at the market offering" program pursuant to which Wainwright will act as sales agent.

The Company filed the June 2, 2025 prospectus supplement to amend the ATM Prospectus to update the maximum amount of shares that it is eligible to sell from and after June 2, 2025, and to specify the value of common stock it would be permitted to sell in any 12 calendar month period under General Instruction I.B.6 of Form S-3. As of June 2, 2025, the Company could only offer and sell shares of its common stock having an aggregate offering price of up to $3,398,000. However, in the event that the Company's public float increases or decreases, it may sell securities in public primary offerings on Form S-3 with a value up to one-third of the Company's public float, in each case calculated pursuant to General Instruction I.B.6 of Form S-3 and subject to the terms of the Agreement. In the event that the Company's public float increases above $75.0 million, it will no longer be subject to the limits in General Instruction I.B.6 of Form S-3. If the Company's public float increases such that it may sell additional amounts under the Agreement and the Form S-3 registration statement of which the ATM Prospectus is a part, the Company will file another prospectus supplement prior to making additional sales. Through the date hereof, the Company has sold securities with an aggregate market value of approximately $684,467 pursuant to General Instruction I.B.6 of Form S-3.

DLA Piper LLP, counsel to the Company, has issued a legal opinion relating to the shares of the Company's common stock that may be issued pursuant to the at-the-market offering program under the ATM Prospectus. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 hereto.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits** |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [5.1](exh_51.htm) | [Opinion of DLA Piper LLP](exh_51.htm) |
| [23.1](exh_51.htm) | [Consent of DLA Piper LLP (included in Exhibit 5.1)](exh_51.htm) |
| 104 | Cover Page Interactive Data File (embedded within the XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Predictive Oncology Inc.** | **Predictive Oncology Inc.** |
| Date: June 6, 2025 | By: | /s/ Josh Blacher |
|  |  | Name: Josh Blacher |
|  |  | Title: Interim Chief Financial Officer |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](dlapiper.jpg) | **DLA Piper LLP (US)**<br> 3203 Hanover Street<br> Suite 100<br> Palo Alto, CA 94304-1123<br> www.dlapiper.com<br>**T** 650.833.2000<br> **F** 650.833.2001 |

---

June 6, 2025

Predictive Oncology Inc.

91 43<sup>rd</sup> Street, Suite 110

Pittsburgh, PA 15201

**Re: Issuance of Up to $4,889,000 of Shares of Common Stock**

Ladies and Gentlemen:

We have served as counsel to Predictive Oncology Inc., a Delaware corporation (the "<u>Company</u>"), in connection with the sale from time to time of up to $4,889,000 of shares of common stock, par value $0.01 per share, of the Company (the "<u>Common Stock</u>") pursuant to the terms of the at-the-market sales agreement, dated as of May 3, 2024 (the "<u>Sales Agreement</u>"), by and between the Company and H.C. Wainwright & Co., LLC (the "<u>Sales Agent</u>").

The Shares have been registered on a Registration Statement on Form S-3 (Registration No. 333-279123), which became effective under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), on May 6, 2024 (the "<u>Registration Statement</u>").

In connection with our representation of the Company, and as a basis for the opinion expressed herein, we have reviewed originals or copies, certified or otherwise identified to our satisfaction, of the following documents (collectively, the "<u>Documents</u>"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the
 Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the
 prospectus supplement, dated April 18, 2025, filed with the Securities and Exchange Commission
 (the " <u>Commission</u> ") pursuant to Rule 424(b) under the Securities Act, for
 an offering of up to $1,491,000 of shares of common stock of the Company, together with the
 base prospectus and prospectus supplement, both dated May 21, 2024 (collectively, " <u>Prospectus 1</u> ");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the
 prospectus supplement, dated June 2, 2025, filed with the Commission pursuant to Rule 424(b)
 under the Securities Act, for an offering of up to $3,398,000 of shares of common stock of
 the Company, together with the base prospectus and prospectus supplement, both dated May
 21, 2024, and the prospectus supplement dated April 18, 2025 (collectively, " <u>Prospectus 2</u> " and together with Prospectus 1, the " <u>Prospectuses</u> ");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) the
 Certificate of Incorporation of the Company, together with all amendments and supplements
 thereto filed through the date hereof (the " <u>Charter</u> "), as certified as
 of a recent date by the Secretary of State of the State of Delaware (the " <u>SOS</u> "),
 and by the Secretary of the Company to be in effect on the date hereof;

![](dlapiper.jpg)

Predictive Oncology Inc.

June 6, 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) the
 Second Amendment and Restated Bylaws of the Company, as amended and restated to the date
 hereof (the " <u>Bylaws</u> "), as certified by the Secretary of the Company to
 be in effect on the date hereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) resolutions
 adopted by the Board of Directors of the Company (the " <u>Board</u> ") on June
 5, 2025 and May 2, 2024, relating to (i) the filing of the Registration Statement, (ii) the
 offering and sale of the Shares, (ii) the authorization of the execution, delivery and performance
 by the Company of the Sales Agreement, and (iii) the delegation to certain officers of the
 Company (the " <u>Authorized Officers</u> ") of the power to determine, subject
 to certain parameters, the number of Shares and the offering price of each Share to be sold
 from time to time pursuant to the Sales Agreement, as certified by the Secretary of the Company
 to be in effect on the date hereof (collectively, the " <u>Resolutions</u> ");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) the
 Company's Annual Report on Form 10-K for the year ended December 31, 2024 (the " <u>10-K</u> "),
 filed with the Commission pursuant to the Securities Exchange Act of 1934, as incorporated
 by reference in the Prospectuses;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) the
 Sales Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) a
 good standing certificate for the Company, dated as of June 6, 2025, issued by the SOS (the
 " <u>Good Standing Certificate</u> ");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) an
 executed copy of the certificate of the Secretary of the Company (the " <u>Certificate</u> "),
 dated as of the date hereof, as to certain factual matters therein; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) such
 other documents as we have deemed necessary or appropriate to enable us to express the opinions
 set forth below.

In examining the Documents, we have assumed, without independent investigation, the genuineness and validity of all signatures, the legal capacity of all individuals who have executed any of the aforesaid documents, the authenticity of all documents submitted to us as originals, and the conformity with originals of all documents submitted to us as copies (and the authenticity of the originals of such copies), the absence of other agreements or understandings among the parties that would modify the terms of the proposed transactions or the respective rights or obligations of the parties thereunder and the accuracy and completeness of all public records reviewed by us. In making our examination of the Documents, we have assumed that such parties had the power and authority (corporate, trust, partnership or other) to enter into and perform all obligations thereunder, and we have also assumed the due authorization by all requisite action (corporate, trust, partnership or other) and the valid execution and delivery by such parties of such documents and the validity, binding effect and enforceability thereof with respect to such parties. As to any facts material to this opinion, we have relied solely upon the Certificate.

We further assume that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The
 Shares will not be issued or transferred in violation of the restrictions on transfer and
 ownership of shares of stock of the Company set forth in Article V of the Charter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The
 Company will not issue any shares of Common Stock other than the Shares.

![](dlapiper.jpg)

Predictive Oncology Inc.

June 6, 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The
 number of Shares, and the offering price of each Share, to be issued by the Company from
 time to time pursuant to the Sales Agreement will be authorized and approved by the Board
 or the Authorized Officers in accordance with and not in violation of the Delaware General
 Corporation Law (the " <u>DGCL</u> "), the Charter, the Bylaws and the Resolutions
 (with such approvals referred to hereinafter as the " <u>Corporate Proceedings</u> ")
 prior to the issuance thereof and, upon issuance of the Shares, the total number of shares
 of Common Stock issued and outstanding will not exceed the total number of shares of Common
 Stock that the Company is then authorized to issue under the Charter.

Based upon the foregoing, and subject to the assumptions, limitations and qualifications stated herein, it is our opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The
 Company is a corporation validly existing under the laws of the State of Delaware and is
 in good standing with the SOS.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The
 Shares have been duly authorized and, when and to the extent issued against payment therefor
 in accordance with the Corporate Proceedings and the terms of the Sales Agreement, will be
 validly issued, fully paid and non-assessable.

In addition to the qualifications set forth above, the foregoing opinion is further qualified as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The
 opinion in paragraph (1) with respect to the existence and good standing of the Company is
 based solely on the Good Standing Certificate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The
 foregoing opinion is rendered as of the date hereof. We assume no obligation to update such
 opinion to reflect any facts or circumstances that may hereafter come to our attention or
 changes in the law which may hereafter occur.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) We
 do not express any opinion herein concerning any law other than the DGCL (including the statutory
 provisions, all applicable provisions of the Delaware Constitution and the reported judicial
 decisions interpreting the foregoing). This opinion concerns only the effect of such laws
 (exclusive of the principles of conflict of laws) as currently in effect. As to matters of
 such laws, we have based our opinion solely upon our examination of such laws and the rules
 and regulations of the authorities administering such laws, all as reported in standard,
 unofficial compilations. The opinion expressed herein is subject to the effect of judicial
 decisions which may permit the introduction of parol evidence to modify the terms or the
 interpretation of agreements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) This
 opinion is limited to the matters set forth herein, and no other opinion should be inferred
 beyond the matters expressly stated.

This opinion is being furnished to you for submission to the Commission as an exhibit to the Company's Current Report on Form 8-K relating to the Shares (the "<u>Current Report</u>") and supplements our opinion dated May 3, 2024 previously filed as Exhibit 5.1 to the Registration Statement. We hereby consent to the filing of this opinion with the Commission as Exhibit 5.1 to the Current Report on the date hereof and to the use of the name of our firm in the section entitled "Legal Matters" in the Prospectuses.

![](dlapiper.jpg)

Predictive Oncology Inc.

June 6, 2025

In giving our consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ DLA Piper LLP (US) |
| **DLA PIPER LLP (US)** |

---